荧光原位杂交与免疫组化检测乳腺癌组织HER-2基因扩增或蛋白表达情况的比较分析  

A Comparative Study of the Methods of Fluorescence in Situs Hybridization and Immunohistochemistry in Detecting HER-2 in Breast Cancer Tissues

作　　者：万美珍[1] 凌扬[1] 徐志毅[1] 刘永萍[1] 周林艳[1] 杨荣华[1] 

机构地区：[1]常州市肿瘤医院,江苏常州213002

出　　处：《肿瘤基础与临床》2010年第1期16-18,共3页journal of basic and clinical oncology

摘　　要：目的评估免疫组织化学(IHC)法检测乳腺癌组织中HER-2蛋白表达和荧光原位杂交(FISH)法检测其HER-2基因扩增在乳腺癌分子靶向治疗中的临床意义。方法采用IHC法及FISH法分别检测47例乳腺癌组织中HER-2蛋白表达及HER-2基因扩增情况。结果47例乳腺癌石蜡标本中,HER-2蛋白表达(+++)20例(42.55%),(++)10例(21.28%),(+)17例(36.17%);HER-2基因扩增22例(46.81%),无扩增25例(53.19%),其中17号染色体多体5例(10.64%)。两种检测结果呈正相关(rs=0.415,P<0.05)。结论IHC法检测乳腺癌组织中HER-2蛋白表达可以作为是否应用赫赛汀的初筛;HER-2蛋白表达阳性的病例有必要进一步进行HER-2基因扩增检测,来确定临床治疗是否应用赫赛汀。Objective To explore the clinical significance of the expression of HER-2 protein by immunohistochemistry（IHC）and the amplification of HER-2 gene by fluorescence in situs hybridization（FISH） in molecular targeting therapy of breast cancer.Methods The expressions of HER-2 protein and the amplification of HER-2 gene in 47 breast cancer tissues were detected by IHC and FISH,respectively.Results The number of patients showed IHC（＋＋＋）,IHC（＋＋）and IHC（＋）was 20 cases（42.55%）,10 cases（21.28%）and 17 cases（36.17%）,respectively.The amplification of HER-2 gene existed in 22 cases（46.81%）,no amplification existed in 25 cases,and 5 cases showed chromosome 17 polysomy.There was positive correlation between the two results（rs=0.415,P〈0.05）.Conclusion Before herceptin therapy,the immunohistochemistry can be first used to detect the expressions of HER-2 protein,and then in the cases with positive expressions of HER-2,the amplifications of HER-2 gene should be further tested to guide the herceptin therapy in the treatment of breast cancer.

关 键 词：乳腺癌 HER-2 荧光原位杂交 免疫组化法 

分 类 号：R737.9[医药卫生—肿瘤]